1801.HK
Innovent Biologics, Inc.
1801.HK
(1.5)41,50 HKD
-8.22% ROA
-12.72% ROE
-40.51x PER
59.405.776.080,00 HKD
32.02% DER
0% Yield
-27.26% NPM
Innovent Biologics, Inc. Stock Analysis
Innovent Biologics, Inc. Fundamental Analysis
Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.
| # | Analysis | Rating |
|---|---|---|
| 1 |
DER
The stock has a minimal amount of debt (32%) relative to its ownership, showcasing a strong financial position and lower risk for investors. |
|
| 2 |
Revenue Growth
With a track record of consistent revenue growth in the past five years, this company presents a compelling opportunity. |
|
| 3 |
Assets Growth
With continuous growth in revenue over the last five years, this company has proven to be a lucrative investment option, showcasing its strong financial performance. |
|
| 4 |
ROE
The stock's ROE indicates a negative return (-78.45%) on shareholders' equity, suggesting poor financial performance. |
|
| 5 |
ROA
The stock's ROA (-8.22%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment. |
|
| 6 |
PBV
The stock's elevated P/BV ratio (5.8x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value. |
|
| 7 |
Net Profit Growth
This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity. |
|
| 8 |
Graham Number
The company's Graham number indicates that it is overvalued compared to its stock price, suggesting a potentially unfavorable investment opportunity. |
|
| 9 |
Dividend Growth
The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice. |
|
| 10 |
Dividend
No dividends from the company in the past three years raises doubts about its profitability for shareholders. |
|
| 11 |
Buffet Intrinsic Value
Based on Warren Buffett's formula, the company's stock seems overpriced (-81), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value. |
Innovent Biologics, Inc. Technical Analysis
Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.
| # | Analysis | Recommendation |
|---|---|---|
| 1 | Awesome Oscillator | Hold |
| 2 | MACD | Sell |
| 3 | RSI | Hold |
| 4 | Stoch RSI | Sell |
Innovent Biologics, Inc. Price Chart
Financial Statements
Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.
Income Statements
An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.
Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.
| Year | Revenue | Growth |
|---|---|---|
| 2016 | 32.127.154 | |
| 2017 | 18.538.000 | -73.3% |
| 2018 | 9.477.000 | -95.61% |
| 2019 | 1.047.525.000 | 99.1% |
| 2020 | 3.843.819.000 | 72.75% |
| 2021 | 4.269.729.000 | 9.98% |
| 2022 | 5.243.960.060 | 18.58% |
Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.
| Year | Research and Development Expenses | Growth |
|---|---|---|
| 2016 | 384.653.000 | |
| 2017 | 611.922.000 | 37.14% |
| 2018 | 1.221.687.000 | 49.91% |
| 2019 | 1.294.724.000 | 5.64% |
| 2020 | 1.851.453.000 | 30.07% |
| 2021 | 2.478.067.000 | 25.29% |
| 2022 | 3.840.584.892 | 35.48% |
General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.
| Year | General and Administrative Expenses | Growth |
|---|---|---|
| 2016 | 57.380.000 | |
| 2017 | 87.768.000 | 34.62% |
| 2018 | 277.502.000 | 68.37% |
| 2019 | 255.299.000 | -8.7% |
| 2020 | 436.872.000 | 41.56% |
| 2021 | 884.027.000 | 50.58% |
| 2022 | 968.069.492 | 8.68% |
EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.
| Year | EBITDA | Growth |
|---|---|---|
| 2016 | -454.064.000 | |
| 2017 | -635.928.000 | 28.6% |
| 2018 | -5.741.776.000 | 88.92% |
| 2019 | -1.576.720.000 | -264.16% |
| 2020 | -734.512.000 | -114.66% |
| 2021 | -2.908.112.000 | 74.74% |
| 2022 | -3.472.228.080 | 16.25% |
Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.
| Year | Gross Profit | Growth |
|---|---|---|
| 2016 | 32.127.154 | |
| 2017 | 90.009.929 | 64.31% |
| 2018 | 10.788.720 | -734.3% |
| 2019 | 922.647.000 | 98.83% |
| 2020 | 3.456.058.000 | 73.3% |
| 2021 | 3.696.689.000 | 6.51% |
| 2022 | 3.719.797.180 | 0.62% |
Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.
| Year | Net Profit | Growth |
|---|---|---|
| 2016 | -504.204.000 | |
| 2017 | -562.318.000 | 10.33% |
| 2018 | -5.771.492.000 | 90.26% |
| 2019 | -1.776.813.000 | -224.82% |
| 2020 | -998.421.000 | -77.96% |
| 2021 | -3.138.053.000 | 68.18% |
| 2022 | -2.781.354.216 | -12.82% |
EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.
| Year | Earning per Share (EPS) | Growth |
|---|---|---|
| 2016 | 0 | |
| 2017 | -1 | 0% |
| 2018 | -17 | 100% |
| 2019 | -2 | -1600% |
| 2020 | -1 | 0% |
| 2021 | -2 | 100% |
| 2022 | -2 | -100% |
Cashflow Statements
Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.
Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.
| Year | Free Cashflow | Growth |
|---|---|---|
| 2016 | -421.437.000 | |
| 2017 | -583.241.000 | 27.74% |
| 2018 | -1.328.758.000 | 56.11% |
| 2019 | -2.030.346.000 | 34.56% |
| 2020 | -1.079.466.000 | -88.09% |
| 2021 | -3.872.359.000 | 72.12% |
| 2022 | -894.075.587 | -333.11% |
Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.
| Year | Operating Cashflow | Growth |
|---|---|---|
| 2016 | -362.993.000 | |
| 2017 | -492.270.000 | 26.26% |
| 2018 | -1.016.019.000 | 51.55% |
| 2019 | -1.664.473.000 | 38.96% |
| 2020 | -307.688.000 | -440.96% |
| 2021 | -2.024.843.000 | 84.8% |
| 2022 | -629.303.568 | -221.76% |
Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.
| Year | Capital Expenditure | Growth |
|---|---|---|
| 2016 | 58.444.000 | |
| 2017 | 90.971.000 | 35.76% |
| 2018 | 312.739.000 | 70.91% |
| 2019 | 365.873.000 | 14.52% |
| 2020 | 771.778.000 | 52.59% |
| 2021 | 1.847.516.000 | 58.23% |
| 2022 | 264.772.019 | -597.78% |
Balance Sheet
Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.
Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.
| Year | Equity | Growth |
|---|---|---|
| 2016 | -1.383.924.000 | |
| 2017 | -1.942.548.000 | 28.76% |
| 2018 | 4.194.414.000 | 146.31% |
| 2019 | 4.756.131.000 | 11.81% |
| 2020 | 8.779.770.000 | 45.83% |
| 2021 | 10.330.397.000 | 15.01% |
| 2022 | 10.729.949.000 | 3.72% |
| 2023 | 10.783.217.000 | 0.49% |
Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.
| Year | Assets | Growth |
|---|---|---|
| 2016 | 2.815.800.000 | |
| 2017 | 2.457.216.000 | -14.59% |
| 2018 | 6.112.577.000 | 59.8% |
| 2019 | 7.230.529.000 | 15.46% |
| 2020 | 11.834.996.000 | 38.91% |
| 2021 | 16.243.713.000 | 27.14% |
| 2022 | 17.588.845.000 | 7.65% |
| 2023 | 17.897.036.000 | 1.72% |
Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.
| Year | Liabilities | Growth |
|---|---|---|
| 2016 | 3.774.018.000 | |
| 2017 | 4.079.344.000 | 7.48% |
| 2018 | 1.918.163.000 | -112.67% |
| 2019 | 2.474.398.000 | 22.48% |
| 2020 | 3.055.226.000 | 19.01% |
| 2021 | 5.913.316.000 | 48.33% |
| 2022 | 6.858.896.000 | 13.79% |
| 2023 | 7.113.819.000 | 3.58% |
Innovent Biologics, Inc. Financial Ratio (TTM)
Valuation Metrics
- Revenue per Share
- 1.71
- Net Income per Share
- -0.91
- Price to Earning Ratio
- -40.51x
- Price To Sales Ratio
- 22.95x
- POCF Ratio
- -44.76
- PFCF Ratio
- -33.64
- Price to Book Ratio
- 5.16
- EV to Sales
- 23.76
- EV Over EBITDA
- -35.89
- EV to Operating CashFlow
- -49.51
- EV to FreeCashFlow
- -34.85
- Earnings Yield
- -0.02
- FreeCashFlow Yield
- -0.03
- Market Cap
- 59,41 Bil.
- Enterprise Value
- 61,53 Bil.
- Graham Number
- 12.05
- Graham NetNet
- 0.78
Income Statement Metrics
- Net Income per Share
- -0.91
- Income Quality
- 0.91
- ROE
- -0.78
- Return On Assets
- -0.08
- Return On Capital Employed
- -0.16
- Net Income per EBT
- 0.96
- EBT Per Ebit
- 0.6
- Ebit per Revenue
- -0.48
- Effective Tax Rate
- -0.12
Margins
- Sales, General, & Administrative to Revenue
- 0.18
- Research & Developement to Revenue
- 0.73
- Stock Based Compensation to Revenue
- 0.09
- Gross Profit Margin
- 0.71
- Operating Profit Margin
- -0.48
- Pretax Profit Margin
- -0.28
- Net Profit Margin
- -0.27
Dividends
- Dividend Yield
- 0
- Dividend Yield %
- 0
- Payout Ratio
- 0
- Dividend Per Share
- 0
Operating Metrics
- Operating Cashflow per Share
- -0.82
- Free CashFlow per Share
- -1.17
- Capex to Operating CashFlow
- 0.42
- Capex to Revenue
- -0.2
- Capex to Depreciation
- -3.08
- Return on Invested Capital
- -0.11
- Return on Tangible Assets
- -0.08
- Days Sales Outstanding
- 0
- Days Payables Outstanding
- 104.97
- Days of Inventory on Hand
- 630.57
- Receivables Turnover
- 0
- Payables Turnover
- 3.48
- Inventory Turnover
- 0.58
- Capex per Share
- -0.35
Balance Sheet
- Cash per Share
- 5,05
- Book Value per Share
- 7,12
- Tangible Book Value per Share
- 7.12
- Shareholders Equity per Share
- 7.12
- Interest Debt per Share
- 2.11
- Debt to Equity
- 0.32
- Debt to Assets
- 0.19
- Net Debt to EBITDA
- -1.24
- Current Ratio
- 3.96
- Tangible Asset Value
- 9,59 Bil.
- Net Current Asset Value
- 4,27 Bil.
- Invested Capital
- 0.32
- Working Capital
- 8,51 Bil.
- Intangibles to Total Assets
- 0.07
- Average Receivables
- 0,00 Bil.
- Average Payables
- 0,27 Bil.
- Average Inventory
- 1364454500
- Debt to Market Cap
- 0.06
Dividends
Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.
| Year | Dividends | Growth |
|---|
Innovent Biologics, Inc. Profile
About Innovent Biologics, Inc.
Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma. The company also offers Byvasda for the treatment of several malignant tumors; Halpryza for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and Wegener's granulomatosis; Pemazyre for the treatment of adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib for the treatment of adult patients with tyrosine kinase inhibitor; and Cyramza to treat four different types of cancers. In addition, it engages in the development of IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein for ocular fundus disease; IBI-306, a human monoclonal antibody to treat hypercholesterolemia; IBI-310, a recombinant human anti CTLA-4 monoclonal antibody for liver cancer and renal cell carcinoma. Further the company develops IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for the treatment of adults with relapsed or refractory multiple myeloma; IBI-376 for the treatment of recurrent or refractory follicular lymphoma; and IBI-112 for the treatment of psoriasis. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. The company has strategic collaborations with NeoCura Bio-Medical Technology Co. Ltd.; Roche Group; Ascentage Pharma Group International; Eli Lilly and Company; Roche Group; and Bolt Biotherapeutics, Inc. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.
- CEO
- Dr. De-Chao Yu Ph.D.
- Employee
- 4.872
- Address
-
168 Dongping Street
Suzhou, 215123
Innovent Biologics, Inc. Executives & BODs
| # | Name | Age |
|---|---|---|
| 1 |
Mr. Blake Salisbury Senior Vice President |
70 |
| 2 |
Ms. Yanju Wang Joint Company Secretary |
70 |
| 3 |
Mr. Dongming Wang Senior Vice President |
70 |
| 4 |
Mr. Hao Xi Ede Executive Director & Fund Managing Partner |
70 |
| 5 |
Dr. Yong Jun Liu M.D., Ph.D. President |
70 |
| 6 |
Dr. Hui Zhou Ph.D. Senior Vice President |
70 |
| 7 |
Ms. Fei You Chief Financial Officer |
70 |
| 8 |
Mr. Min Liu Chief Commercial Officer |
70 |
| 9 |
Ms. Vivian Zhang Chief People Officer & GM |
70 |
| 10 |
Dr. De-Chao Yu Ph.D. Co-Founder, Chairman & Chief Executive Officer |
70 |
Innovent Biologics, Inc. Competitors
